Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CV9104
- Development stage
- Discontinued
- Lead developer
- BioNTech
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
CV9104 is an investigational mRNA-based cancer vaccine developed for the treatment of prostate cancer. It is part of CureVac's RNActive platform and consists of six different mRNAs encoding full-length tumor-associated antigens, including PSA (prostate-specific antigen), PSMA (prostate-specific membrane antigen), PAP (prostatic acid phosphatase), MUC1 (mucin 1), and others. Upon intradermal administration, the mRNAs are taken up by cells and translated into their respective antigens, which are then presented to the immune system. This process aims to induce a cytotoxic T lymphocyte response against prostate tumor cells expressing these antigens[1][2][6]. The primary indication for CV9104 has been metastatic castration-resistant prostate cancer[3][5][7]. Clinical trials have evaluated its safety and efficacy in this setting; however, a phase IIb trial did not meet its primary endpoint[8].
- Other names
- mRNA-derived prostate cancer vaccine CV9104RNActive-derived vaccine CV9104
02
Targets
MUC1 (Mucin-1 Antigen)P fimbriaePSA (Puromycin-sensitive aminopeptidase)PSCA (Prostate stem cell antigen)PSMA (Prostate-specific membrane antigen)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on CV9104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CV9104.